DOCSLIB.ORG

The Control of Von Willebrand Factor Multimer Size

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Control of Von Willebrand Factor Multimer Size The control of von Willebrand factor multimer size John Eshantha Pimanda A thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy Faculty of Medicine, University of New South Wales December 2003 Acknowledgements A courageous six year old girl with congenital TTP participated in our treatment trial; I thank her and her parents for their trust. Dr. Julian Paxton, Mr. Andrew Schultz, Ramsay Health and the staff at St. John of God pathology and the children's ward at Mildura Base Hospital made the study possible. Over twenty five patients with a past diagnosis of TTP participated in a study to identify mutations in the thrombospondin-1 gene; I thank them and their physicians for their time and effort. I thank Professor Philip Hogg for supervising my work. The power of his ideas and generosity of spirit have taught me much. I have enjoyed the three years spent in his laboratory. Professor Colin Chesterman has guided my development as a haematologist and a scientist. I have benefited from the clarity of his reasoning and value his mentorship. Professor Beng Chong encouraged me to pursue a career in research at an early stage in my clinical training; Drs. Robert Lindeman and Michael Buckley gave of their time and expertise. Ms. Sue Evans, Ms. Janet Argyl, Mr. Robert Casten and Ms. Bernadette O'Reilly in the haematology department at the Prince of Wales Hospital were ever generous with their time and expertise. The staff of the blood bank accommodated my most unreasonable requests. Mr. Peter Taylor and the staff in the molecular genetics department provided valuable technical advice and practical help. Professor Michael Berndt, Monash University and Dr. Emanuel Favaloro, ICPMR Westmead were gracious with time, materials and ideas. My colleagues at the Centre for Vascular Research were a joy to work with. Dr Xing-mai Jiang and Ms. Akiko Maekawa introduced me to the fundamentals of molecular biology and protein expression. Drs. Angelina Lay, Mark Raftery and Troels Wind furthered my understanding in protein chemistry. Ms. Lisa Sun and Ms. Lakmini Weerakoon helped with material preparation and Mr. Geoff Kershaw (at the Royal Prince Alfred Hospital) and Mr. Tim Ganderton with running VWF multimer gels. Dr. Susan Maastricht and Ms. Christine Sutter facilitated the animal work. The National Health and Medical Research Council of Australia provided financial support for which I am most grateful. My parents in law, Rita and Hector Welgampola, with their presence have been a major asset to the completion of this thesis. My parents, Frank and Sriyani Pimanda continue to contribute selflessly to my happiness as they always have. I dedicate this thesis to my wife, Miriam ii Publications arising from this thesis Refereed journal articles published Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital Thrombotic Thrombocytopenic Purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2003 (prepublished online September 25) Pimanda JE, Annis DS, Raftery M, Mosher DF, Chesterman CN, Hogg PJ. The von Willebrand factor-reducing activity of thrombospondin-1 is located in the calcium binding/C-terminal sequence and requires a free thiol at position 974. Blood. 2002 Oct 15; 100(8):2832-8. Pimanda JE, Chesterman CN, Hogg PJ. A Perspective on the Measurement of ADAMTS13 in Thrombotic Thrombocytopaenic Purpura. European Journal of Haematology. 2003 Apr; 70 (4):257-62. Pimanda J, Hogg P. Control ofvon Willebrand factor multimer size and implications for disease. Blood Rev. 2002 Sep; 16 (3):185-92 Pimanda JE, Lowe HC, Hogg PJ, Chesterman CN, Kachigian LM. Novel and emerging therapies in cardiology and haematology. Current Drug Targets­ Cardiovascular & Haematological Disorders, 2003; 3 (2):101-123 iii Refereed journal articles submitted Pimanda JE, Ganderton T, Lawler J, Kershaw G, Maekawa A, Chesterman CN, Hogg PJ. Role ofthrombospondin 1 in control ofvon Willebrand Factor multimer size in mice. Referenced abstracts Pimanda JE, Xie LJ, Chesterman CN, Hogg PJ. Control ofvon Willebrand Factor Multimer Size. Blood 2001 Nov 16, 98(11): 160a. Pimanda JE, Annis DS, Raftery M, Mosher DF, Chesterman CN and Hogg PJ. The von Willebrand Factor Reducing Activity ofThrombospondin-1 Centres around a Free Thiol at Position 974. Blood2002 Nov 16, 100(11): 980a. Pimanda JE, Kershaw G, Lawler J, Chesterman CN, Hogg PJ. The control of von Willebrand Factor multimer size by Thrombospondin-1. Journal of Thrombosis and Haemostasis 2003 (in press). Presented abstracts Xie LJ, Pimanda JE, Chesterman CN, Hogg PJ. The control ofvon Willebrand factor multimer size by thrombospondin-1. Haematology Society of Australia and New Zealand/ Australasian Society of Blood Transfusion/ Australasian Society of Thrombosis and Haemostasis Joint Annual meeting.(HSANZ/ ASBT / ASTH) Brisbane. September 2001. iv Pimanda JE, Annis DS, Raftery M, Mosher DF, Chesterman CN and Hogg PJ. Localization of the von Willebrand factor reducing activity of thrombospondin-1. The Australian Society of Medical Research Scientific Meeting. Sydney. June 2002. Pimanda JE, Annis DS, Raftery M, Mosher DF, Chesterman CN and Hogg PJ. The von Willebrand Factor Reducing Activity ofThrombospondin-1 is located in the Calcium-binding/C-globular Domain and Requires a Free Thiol at Position 974. HSANZ/ASBT/ASTH Joint Annual Meeting. Adelaide. September 2002. Pimanda JE, Kershaw G, Lawler J, Chesterman CN, Hogg PJ. The control of vWF multimer size by thrombospondin-1. A study of Plasma and platelet VWF multimer size in thrombospondin-1 null mice. The Royal College of Pathologists of Australasia­ Pathology Update 2003. Sydney. March 2003. Pimanda JE, Ganderton T, Kershaw G, Lawler J, Chesterman CN, Hogg PJ. Role of thrombospondin-1 in the control of VWF multimer size in mice. The Australian Vascular Biology Society and Australian Atherosclerosis Society-annual scientific meeting. Ballarat, Victoria, September 2003. Pimanda JE, Ganderton,T, Kershaw G, Lawler J, Chesterman CN, Hogg PJ. Role of thrombospondin-1 in the control ofVWF multimer size in mice. HSANZ/ASBT/ASTH­ joint annual scientific meeting, Christchurch, New Zealand, October 2003 V Table of contents page List of abbreviations 1 Abstract 4 Preface 6 Chapter 1: Literature review 8 Introduction 9 1.1 von Willebrand factor 10 1.1.1 Synthesis 10 1.1.2 Storage and secretion 12 1.2 Control of plasma VWF multimer size-by proteolytic cleavage 13 1.2.1 ADAMTS13-a novel VWF cleaving protease 15 1.2.1.1 Tracing the ADAMTS13 gene 15 1.2.1.2 Phylogeny of ADAMTS13 17 1.2.1.3 The ADAMTS13 proenzyme 17 1.2.1.4 The domain structure of ADAMTS13 and relevance to function 19 1.2.1.5 The Tyr1605 and Met1606 cleavage site resides within the A2 domain of VWF 21 1.2.1.6 Glycosylation of ADAMTS13 23 1.2.1.7 Measurement of ADAMTS13 activity in plasma 24 1.3 Control of plasma VWF multimer size -by a VWF reductase 29 1.3.1 The thrombospondin gene family 35 1.3.1.1 Evolution of the thrombospondin gene family 37 1.3.1.2 The structure ofTSP-1 and relevance to function 38 1.3.1.3 The structure and function relationship between TSP-1 and VWF 44 vi 1.3.1.4 TSP-1 as an enzyme inhibitor 45 1. 3 .1. 5 The phenotype of the TSP-1 null mouse 46 1.4 Control of platelet VWF multimer size 47 1.5 VWF multimer size and disease 50 1.5.1 Deficiency of high molecular weight VWF multimers and bleeding 50 1.5.2 Persistence of high molecular weight VWF multimers and thrombosis 52 1.5.2.1 The thrombotic microangiopathies 52 1.5.2.2 VWF: atherosclerosis and arterial thrombosis 56 1.5.2.3 Pre-eclampsia, eclampsia and the HELLP syndrome 58 Chapter 2: The VWF reducing activity ofthrombospondin-1 60 2.1 Summary 61 2.2 Introduction 62 2.3 Materials and methods 64 2.4 Results 69 2.5 Discussion 81 Chapter 3: Role ofthrombospondin-1 in the control of VWF multimer size in mice 85 3.1 Summary 86 3.2 Introduction 87 3.3 Materials and methods 90 3.4 Results 97 3.5 Discussion 112 vii Chapter 4: Role ofthrombospondin-1 in TTP 117 5.1 Summary 118 5.2 Introduction 119 5.3 Patients and methods 120 5.4 Results and discussion 125 Chapter 5: TTP in association with a mutation in the second CUB domain of ADAMTS13 135 4.1 Summary 136 4.2 Introduction 136 4.3 Materials and methods 138 4.4 Results 141 4.5 Discussion 146 Chapter 6: Summary and future directions 150 References 157 viii List of abbreviations and acronyms used AEBSF 4-(2-aminoethyl) benzensulfonyl fluoride ADAM ~ gisintegrin-like ~d metalloprotease ADAMTS ~ .disintegrin-like ~nd metalloprotease with thrombo.s_pondin type 1 motif BSA bovine serum albumin CBA collagen binding activity CK cysteine knot COMP cartilage oligomeric matrix protein COS-7 cell line (monkey, African green, Kidney) fibroblast like CP123 procollagen and properdin (type 1) repeats 1-3 CPA cone and plate (let) analyzer CUB £Omplement components Cl r/Cls, sea yrchin epidermal growth factor and .b_one morphogenetic protein DDAVP 1-desamino-8-D-arginine vasopressin DTNB 5, 5 '-dithiobis (2-nitrobenzoic acid) E3CaG third type 2, type 3 and C-terminal globular domain EDTA ethylenediaminetetraacetic acid EGF epidermal growth factor ELISA enzyme linked immunosorbant assay ER endoplasmic reticulum FFP fresh frozen plasma 1 GSH reduced glutathione HBS HEPES buffered saline HELLP haemolysis, elevated liver function and low proteins HEPES (N-[2-Hydroxyethyl] piperazine-N' -[2-ethanesulfonic acid]) HIV human immunodeficiency virus HMWM high molecular weight multimers HUS haemolytic uremic syndrome HUVEC human umbilical vein endothelial cell
Load more

Recommended publications
  • Human ADAM12 Quantikine ELISA
    Quantikine® ELISA Human ADAM12 Immunoassay Catalog Number DAD120 For the quantitative determination of A Disintegrin And Metalloproteinase domain- containing protein 12 (ADAM12) concentrations in cell culture supernates, serum, plasma, and urine. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Quantikine® ELISA
    Quantikine® ELISA Human ADAMTS13 Immunoassay Catalog Number DADT130 For the quantitative determination of human A Disintegrin And Metalloproteinase with Thombospondin type 1 motif, 13 (ADAMTS13) concentrations in cell culture supernates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................4 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • ADAMTS13 and 15 Are Not Regulated by the Full Length and N‑Terminal Domain Forms of TIMP‑1, ‑2, ‑3 and ‑4
    BIOMEDICAL REPORTS 4: 73-78, 2016 ADAMTS13 and 15 are not regulated by the full length and N‑terminal domain forms of TIMP‑1, ‑2, ‑3 and ‑4 CENQI GUO, ANASTASIA TSIGKOU and MENG HUEE LEE Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China Received June 29, 2015; Accepted July 15, 2015 DOI: 10.3892/br.2015.535 Abstract. A disintegrin and metalloproteinase with thom- proteolysis activities associated with arthritis, morphogenesis, bospondin motifs (ADAMTS) 13 and 15 are secreted zinc angiogenesis and even ovulation [as reviewed previously (1,2)]. proteinases involved in the turnover of von Willebrand factor Also known as the VWF-cleaving protease, ADAMTS13 and cancer suppression. In the present study, ADAMTS13 is noted for its ability in cleaving and reducing the size of the and 15 were subjected to inhibition studies with the full-length ultra-large (UL) form of the VWF. Reduction in ADAMTS13 and N-terminal domain forms of tissue inhibitor of metallo- activity from either hereditary or acquired deficiency causes proteinases (TIMPs)-1 to -4. TIMPs have no ability to inhibit accumulation of UL-VWF multimers, platelet aggregation and the ADAMTS proteinases in the full-length or N-terminal arterial thrombosis that leads to fatal thrombotic thrombocy- domain form. While ADAMTS13 is also not sensitive to the topenic purpura [as reviewed previously (1,3)]. By contrast, hydroxamate inhibitors, batimastat and ilomastat, ADAMTS15 ADAMTS15 is a potential tumor suppressor. Only a limited app can be effectively inhibited by batimastat (Ki 299 nM). In number of in-depth investigations have been carried out on the conclusion, the present results indicate that TIMPs are not the enzyme; however, expression and profiling studies have shown regulators of these two ADAMTS proteinases.
    [Show full text]
  • ADAMTS Proteases in Vascular Biology
    Review MATBIO-1141; No. of pages: 8; 4C: 3, 6 ADAMTS proteases in vascular biology Juan Carlos Rodríguez-Manzaneque 1, Rubén Fernández-Rodríguez 1, Francisco Javier Rodríguez-Baena 1 and M. Luisa Iruela-Arispe 2 1 - GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain 2 - Department of Molecular, Cell, and Developmental Biology, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA Correspondence to Juan Carlos Rodríguez-Manzaneque and M. Luisa Iruela-Arispe: J.C Rodríguez-Manzaneque is to be contacted at: GENYO, 15 PTS Granada - Avda. de la Ilustración 114, Granada 18016, Spain; M.L. Iruela-Arispe, Department of Molecular, Cell and Developmental Biology, UCLA, 615 Charles Young Drive East, Los Angeles, CA 90095, USA. [email protected]; [email protected] http://dx.doi.org/10.1016/j.matbio.2015.02.004 Edited by W.C. Parks and S. Apte Abstract ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases comprise the most recently discovered branch of the extracellular metalloenzymes. Research during the last 15 years, uncovered their association with a variety of physiological and pathological processes including blood coagulation, tissue repair, fertility, arthritis and cancer. Importantly, a frequent feature of ADAMTS enzymes relates to their effects on vascular-related phenomena, including angiogenesis. Their specific roles in vascular biology have been clarified by information on their expression profiles and substrate specificity. Through their catalytic activity, ADAMTS proteases modify rather than degrade extracellular proteins. They predominantly target proteoglycans and glycoproteins abundant in the basement membrane, therefore their broad contributions to the vasculature should not come as a surprise.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • R&D Assay for Alzheimer's Disease
    R&DR&D assayassay forfor Alzheimer’sAlzheimer’s diseasedisease Target screening⳼ Ⲽ㬔 antibody array, ᢜ⭉㬔 ⸽ἐⴐ Amyloid β-peptide Alzheimer’s disease⯸ ኸᷠ᧔ ᆹ⸽ inhibitor, antibody, ELISA kit Surwhrph#Surilohu#Dqwlerg|#Duud| 6OUSFBUFE 1."5SFBUFE )41 $3&# &3, &3, )41 $3&# &3, &3, 壤伡庰䋸TBNQMF ɅH 侴䋸嵄䍴䋸BOBMZUFT䋸䬱娴哜塵 1$ 1$ 1$ 1$ 5IFNPTUSFGFSFODFEBSSBZT 1$ 1$ QQ α 34, .4, 503 Q α 34, .4, 503 %SVHTDSFFOJOH0òUBSHFUFòFDUT0ATHWAY涭廐 6OUSFBUFE 堄币䋸4BNQMF侴䋸8FTUFSOPS&-*4"䍘䧽 1."5SFBUFE P 8FTUFSOCMPU廽喜儤应侴䋸0, Z 4VCTUSBUF -JHIU )31DPOKVHBUFE1BO "OUJQIPTQIPUZSPTJOF .FBO1JYFM%FOTJUZ Y $BQUVSF"OUJCPEZ 5BSHFU"OBMZUF "SSBZ.FNCSBOF $3&# &3, &3, )41 .4, Q α 34, 503 Human XL Cytokine Array kit (ARY022, 102 analytes) Adiponectin,Aggrecan,Angiogenin,Angiopoietin-1,Angiopoietin-2,BAFF,BDNF,Complement,Component C5/C5a,CD14,CD30,CD40L, Chitinase 3-like 1,Complement Factor D,C-Reactive Protein,Cripto-1,Cystatin C,Dkk-1,DPPIV,EGF,EMMPRIN,ENA-78,Endoglin, Fas L,FGF basic,FGF- 7,FGF-19,Flt-3 L,G-CSF,GDF-15,GM-CSF,GRO-α,Grow th Hormone,HGF,ICAM-1,IFN-γ,IGFBP-2,IGFBP-3, IL-1α,IL-1β, IL-1ra,IL-2,IL-3,IL-4,IL- 5,IL-6,IL-8, IL-10,IL-11,IL-12, IL-13,IL-15,IL-16,IL-17A,IL-18 BPa,IL-19,IL-22, IL-23,IL-24,IL-27, IL-31,IL-32α/β/γ,IL-33,IL-34,IP-10,I-TAC,Kallikrein 3,Leptin,LIF,Lipocalin-2,MCP-1,MCP-3,M-CSF,MIF,MIG,MIP-1α/MIP-1β,MIP-3α,MIP-3β,MMP-9, Myeloperoxidase,Osteopontin, p70, PDGF-AA, PDGF-AB/BB,Pentraxin-3, PF4, RAGE, RANTES,RBP4,Relaxin-2, Resistin,SDF-1α,Serpin E1, SHBG, ST2, TARC,TFF3,TfR,TGF- ,Thrombospondin-1,TNF-α, uPAR, VEGF, Vitamin D BP Human Protease (34 analytes) /
    [Show full text]
  • Gene Symbol Category ACAN ECM ADAM10 ECM Remodeling-Related ADAM11 ECM Remodeling-Related ADAM12 ECM Remodeling-Related ADAM15 E
    Supplementary Material (ESI) for Integrative Biology This journal is (c) The Royal Society of Chemistry 2010 Gene symbol Category ACAN ECM ADAM10 ECM remodeling-related ADAM11 ECM remodeling-related ADAM12 ECM remodeling-related ADAM15 ECM remodeling-related ADAM17 ECM remodeling-related ADAM18 ECM remodeling-related ADAM19 ECM remodeling-related ADAM2 ECM remodeling-related ADAM20 ECM remodeling-related ADAM21 ECM remodeling-related ADAM22 ECM remodeling-related ADAM23 ECM remodeling-related ADAM28 ECM remodeling-related ADAM29 ECM remodeling-related ADAM3 ECM remodeling-related ADAM30 ECM remodeling-related ADAM5 ECM remodeling-related ADAM7 ECM remodeling-related ADAM8 ECM remodeling-related ADAM9 ECM remodeling-related ADAMTS1 ECM remodeling-related ADAMTS10 ECM remodeling-related ADAMTS12 ECM remodeling-related ADAMTS13 ECM remodeling-related ADAMTS14 ECM remodeling-related ADAMTS15 ECM remodeling-related ADAMTS16 ECM remodeling-related ADAMTS17 ECM remodeling-related ADAMTS18 ECM remodeling-related ADAMTS19 ECM remodeling-related ADAMTS2 ECM remodeling-related ADAMTS20 ECM remodeling-related ADAMTS3 ECM remodeling-related ADAMTS4 ECM remodeling-related ADAMTS5 ECM remodeling-related ADAMTS6 ECM remodeling-related ADAMTS7 ECM remodeling-related ADAMTS8 ECM remodeling-related ADAMTS9 ECM remodeling-related ADAMTSL1 ECM remodeling-related ADAMTSL2 ECM remodeling-related ADAMTSL3 ECM remodeling-related ADAMTSL4 ECM remodeling-related ADAMTSL5 ECM remodeling-related AGRIN ECM ALCAM Cell-cell adhesion ANGPT1 Soluble factors and receptors
    [Show full text]
  • Pharmnotes February 2019
    PharmNOTES Summary about new FDA products, generic medication, medical products, and WHAT IS IN THE PIPELINE. From: FEBRUARY 2019 Date: 3/7/2019 ©2019 PharmPiX. All rights reserved Table of Contents Page News 3 New FDA Approved Products 4-12 Jeuveau™ (prabotulinumtoxinA-xvfs) 4-5 Cablivi™ (caplacizumab-yhdp) 6-8 Egaten™ (triclabendazole) 9-10 Esperoct™ (turoctocog alfa pegol) 11-12 New FDA Approved Indications 13-14 New FDA Approved Dosage Forms, Formulations, Combinations, and Other Differences 15 New First-Time Generic Drug Approval 16 Pipeline 17-18 References 19 2 NEWS………………………… Drug Issue Date News/Event Increased risk of 02/21/2019 The FDA has concluded that there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, death with Uloric™ allopurinol. As a result, the Uloric™ prescribing information will include a Boxed Warning. The FDA is also limiting the (febuxostat) approved use of Uloric™ to certain patients who are not treated effectively or experience severe side effects with allopurinol. Recommendations for healthcare professionals: • Reserve Uloric™ for use only in patients who have failed or do not tolerate allopurinol. • Counsel patients about the cardiovascular risk with Uloric™ and advise them to seek medical attention immediately if they experience the following symptoms: chest pain, shortness of breath, rapid or irregular heartbeat, numbness or weakness on one side of the body, dizziness, trouble talking, sudden severe headache. For more details regarding this safety issue, please visit: https://www.fda.gov/Drugs/DrugSafety/ucm631182.htm Risk of blood clots in 02/25/2019 The FDA is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 the lungs and death mg twice daily dose of tofacitinib (Xeljanz™, Xeljanz XR™) was used in patients with rheumatoid arthritis (RA).
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Von Willebrand Factor and ADAMTS13 Activity in Relation to Risk of Dementia
    www.nature.com/scientificreports OPEN Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population- Received: 7 December 2017 Accepted: 21 March 2018 based study Published: xx xx xxxx Frank J. Wolters 1,2, Johan Boender3, Paul S. de Vries4, Michelle A. Sonneveld3, Peter J. Koudstaal2, Moniek P. de Maat3, Oscar H. Franco1, M. Kamran Ikram1,2, Frank W. Leebeek3 & M. Arfan Ikram 1 Low ADAMTS13 activity is associated with an increased risk of cardiovascular disease, which is generally attributed to its proteolytic efects on Von Willebrand factor (VWF). Cardiovascular health is an important determinant of cognitive decline, but the association of either VWF or ADAMTS13 with risk of dementia is unknown. Between 1997–2002, we measured VWF antigen and ADAMTS13 activity in 6055 participants of the population-based Rotterdam Study (mean age 69.3 years, 57.2% women). At baseline, 85 participants had dementia, and during 15 years of follow-up 821 developed dementia. Higher VWF was associated with prevalence and risk of dementia, unafected by concurrent ADAMTS13 activity, but estimates strongly attenuated over time and were no longer statistically signifcant at 4 years of follow-up (relative risks [95% CI] per standard deviation increase– cross-sectional: 1.37 [1.06– 1.77], and longitudinal: 1.05 [0.97–1.14]). In contrast, low ADAMTS13 was associated with increased risk of dementia throughout follow-up (hazard ratio per SD decrease– 1.16 [1.06–1.28]), which alike for ischaemic stroke, was modifed by the presence of diabetes (P-interaction = 0.003). In conclusion, higher VWF and low ADAMTS13 activity are associated with increased risk of dementia, but diferences in time-course and lack of synergistic efects may indicate in part independent underlying mechanisms.
    [Show full text]
  • Molecular Genetics of Von Willebrand Disease”
    MOLECULAR GENETICS OF VON WILLEBRAND DISEASE SUMITHA E Ph.D THESIS 2016 DEPARTMENT OF HAEMATOLOGY & CENTRE FOR STEM CELL RESEARCH (A UNIT OF INSTEM BENGALURU) CHRISTIAN MEDICAL COLLEGE, VELLORE SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY, TRIVANDRUM Thiruvananthapuram MOLECULAR GENETICS OF VON WILLEBRAND DISEASE A THESIS PRESENTED BY SUMITHA E Department of Hematology & Centre for Stem Cell Research (A unit of inStem, Bengaluru) Christian Medical College, Vellore TO THE SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY, TRIVANDRUM Thiruvananthapuram IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE AWARD OF DOCTOR OF PHILOSOPHY 2016 DECLARATION BY STUDENT I, Sumitha E hereby certify that I had personally carried out the work depicted in the thesis, entitled, “Molecular Genetics of Von Willebrand Disease”. No part of the thesis has been submitted for the award of any degree or diploma prior to this date. Signature: Name of the Candidate: Sumitha E Date: i CERTIFICATE BY GUIDE Dr. Alok Srivastava, MD, FRACP, FRCPA, FRCP Professor of Medicine, Department of Hematology, Head, Centre for Stem Cell Research, Christian Medical College, Vellore Tamil Nadu 632002. This is to certify that Ms Sumitha. E in the Department of Hematology of Christian Medical College, Vellore has fulfilled the requirements prescribed for the Ph.D degree of the Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum. The thesis entitled "Molecular Genetics of Von Willebrand Disease" was carried out under my direct supervision. No part of the thesis was submitted for the award of any degree or diploma prior to this date. * Clearance was obtained from Institutional Ethics Committee for carrying out the study.
    [Show full text]